In the BioHarmony Drug Report Database

"Preview" Icon

Pralatrexate

Folotyn (pralatrexate) is a small molecule pharmaceutical. Pralatrexate was first approved as Folotyn on 2009-09-24. It is used to treat t-cell lymphoma peripheral in the USA. The pharmaceutical is active against dihydrofolate reductase. Folotyn’s patents are valid until 2025-05-31 (FDA).

 

Trade Name

 

Folotyn
 

Common Name

 

pralatrexate
 

ChEMBL ID

 

CHEMBL1201746
 

Indication

 

t-cell lymphoma peripheral
 

Drug Class

 

Antimetabolites (folic acid derivatives)

Image (chem structure or protein)

Pralatrexate structure rendering